Big biotechs have and insatiable thirst right now

Big biotechs have and insatiable thirst right now for new drugs as the patent cliff has dampened revenues for many and pipelines are thin for novel drug candidates.  Cancer is of particular interest as the revenue stream for a successful cancer drug can easily tally into the billions annually.  Additionally, a recent report from the Tufts Center for the Study of Drug Development found that cancer drugs are getting faster approval times at the FDA than all other disease categories combined; giving the already in-demand drugs even greater appeal to big pharma.  According to Fierce Biotech , “[the] center concluded that cancer drugs claimed a growing share of the orphan drug market as the total time it requires to take a fast-track drug through development to an approval shrunk by an impressive 1.7 years over the past decade.”

Just because we don't have RESULTS a few days after first dosing (so some can lock in there 50 cents a share profit) doesn't mean that we aren't sitting on the greatest and possibly most financially rewarding company in bio-pharma history!